Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer

Keyphrases

• Neoadjuvant 100%
• Neoadjuvant Chemotherapy 100%
• Muscle-invasive Bladder Cancer 100%
• Platinum-based Chemotherapy 100%
• Lean muscle Mass 100%
• Post-neoadjuvant 54%
• Skeletal muscle Index 45%
• Upper Tract Urothelial Carcinoma 36%
• Cystectomy 36%
• Invasive Urothelial Carcinoma 36%
• Sarcopenia 18%
• Lean muscle 18%
• Platinum-based Neoadjuvant Chemotherapy 18%
• Chemotherapy 9%
• Skeletal muscle 9%
• Soft Tissue 9%
• Increased Mortality 9%
• Bladder 9%
• Doxorubicin 9%
• Gemcitabine 9%
• Cisplatin 9%
• Methotrexate 9%
• Body Composition 9%
• Subcutaneous Adipose Tissue 9%
• Chemotherapy Initiation 9%
• Computed Tomography 9%
• Visceral Adipose Tissue 9%
• Chemotherapy Regimen 9%
• Muscle Mass 9%
• Carboplatin 9%
• Muscle Loss 9%
• Cross-sectional Area 9%
• Tissue Areas 9%
• Consensus Definition 9%
• Median Time 9%
• 6-cycles 9%
• Percent Change 9%
• Median Body 9%
• Vinblastine 9%
• BMI Index 9%
• Dose-dense 9%
• Gemcitabine Plus Cisplatin 9%
• L3 Skeletal muscle Index 9%
• Intramuscular Adipose Tissue 9%

Medicine and Dentistry

• Neoadjuvant Chemotherapy 100%
• Muscle Invasive Bladder Cancer 100%
• Skeletal Muscle 53%
• Bladder 38%
• Cystectomy 30%
• Transitional Cell Carcinoma 30%
• Body Mass Index 23%
• Adipose Tissue 23%
• Gemcitabine 15%
• Sarcopenia 15%
• Cisplatin 15%
• Prevalence 7%
• Carboplatin 7%
• Chemotherapy 7%
• Computer Assisted Tomography 7%
• Cohort Analysis 7%
• Dose Densification 7%
• Doxorubicin 7%
• Methotrexate 7%
• Vinblastine 7%